increased 32 MB due to the fact that the increasing of cash from stock inventory decreased in Q1/2018 - Cash flow from the investment 0.9 MB when compared with Q1/2017 increasing 0.6 MB came from fixed assets
Translation CEN 034-2018 November 13, 2018 Subject : Management Discussion and Analysis for quarter 3-2018 To : The Manager and President The Stock Exchange of Thailand Business operation for 3
Microsoft Word - ACE MDA Q3 22 - EN 1 No. ACE-ACC-4/2022 11 November 2022 Subject Management Discussion and Analysis for the period ended 30 September 2022 To President The Stock Exchange of Thailand
) (25.8) EBIT Ratio (ร้อยละ) 4.3 12.8 (8.5) EBITDA Ratio (ร้อยละ) 16.3 17.3 (1.0) Remarks (1) Comprises of total revenue net dividend income, gain on foreign exchange, interest income and non-operating
Microsoft Word - MD&A FY17 EN (1) February 26, 2018 To President, The Stock Exchange of Thailand Subject Notification on the difference of revenue from sales and net profit YOY by more than 20
1 Ref: AC.024/2019 3 August 2019 Subject: Management discussion and analysis of financial position and operating results To: President and Manager The Stock Exchange of Thailand Overall operating
million, which is increased by Baht 5 million or 19% compared to those of the prior year. It is due to the higher long-term loans used for the acquisition of fixed assets of the Group. Income tax expenses
three-month period ended 31 March 2020, the Company has one-time expenses, which are • Write off withholding tax and corporate income tax prepaid in 2016 • Loss from investment in fixed income fund of 2.1
, Samutsakhon 74000 No. DOD43/2563 May 14, 2020 To: The President The Stock Exchange of Thailand (SET) Subject: Management’s Discussion and Analysis for the first Quarter of 2020 DOD Biotech Public Company
company has investments in the Fixed Income Fund, Fixed Deposit Account and Bonds at total approximately Baht 172 million and the net cash flow from the business operation at average approximately Baht 4